Scholl Hendrik Peter 4

What Happened
Hendrik P. Scholl, Chief Medical Officer of Belite Bio, sold a total of 10,000 American Depositary Shares (ADSs) in multiple open‑market dispositions on June 18, 2026, for aggregate proceeds of $1,452,436. The filing lists five disposals: 96 ADSs @ $143.90 ($13,814); 3,748 ADSs @ $144.66 ($542,192); 4,861 ADSs @ $145.43 ($706,959); 1,199 ADSs @ $146.24 ($175,348); and 96 ADSs @ $147.11 ($14,123). These were sales (not purchases or option exercises).

Key Details

• Transaction date: June 18, 2026 (filed with the SEC on June 22, 2026; filing appears timely).
• Transaction type: Open‑market dispositions (code S = Sale).
• Total shares sold: 10,000 ADSs; total proceeds: $1,452,436 (~$1.45M).
• Shares owned after transaction: Not specified in this filing.
• Notable footnotes:
  • F1: Each ADS represents one ordinary share.
  • F2–F4: Some sales were reported as weighted‑average prices covering price ranges; the reporting person will provide specific breakdowns upon request to the SEC, issuer, or a security holder.
• No indication in the filing of a 10b5‑1 plan, option exercise, gift, or tax withholding related to these sales.

Context
These entries are routine insider sales (dispositions) reported on a Form 4. Sales by executives provide information about insider liquidity but do not, by themselves, indicate the insider’s view of the company’s prospects. Purchases generally carry more weight for signaling conviction; this filing documents only sales.